BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on the MEK inhibitor, ARRY-162, and the pan-cytokine inhibitor, ARRY-797, at the 2008 Annual European Congress of Rheumatology in Paris, France.
